アバレプト懸濁性点眼液 0.3%

CTD 第 2 部 CTD の概要（サマリー）

2.7 臨床概要

2.7.5 参考文献

千寿製薬株式会社

2.7.5 参考文献

1)ドライアイ研究会診療ガイドライン作成委員会．ドライアイ診療ガイドライン．日眼会誌．2019;123:489-592.
2)Sakane Y, Yamaguchi M, Yokoi N, Uchino M, Dogru M, Oishi T, et al. Development and validation of the Dry Eye-Related Quality-of-Life Score questionnaire. JAMA Ophthalmol. 2013;131:1331-8.
3)European Medicines Agency Committee for Medicinal Products for Human Use (CHMP). Guideline on the clinical development of medicinal products intended for the treatment of pain. (15 Dec 2016) EMA/CHMP/970057/2011.
4)Chalmers RL, Begley CG, Caffery B. Validation of the 5-Item Dry Eye Questionnaire (DEQ-5): Discrimination across self-assessed severity and aqueous tear deficient dry eye diagnoses. Cont Lens Anterior Eye. 2010;33:55-60.
5)Schiffman RM, Christianson MD, Jacobsen G, Hirsch JD, Reis BL. Reliability and validity of the Ocular Surface Disease Index. Arch Ophthalmol. 2000;118:615-21.
6)De Paiva CS, Chen Z, Koch DD, Hamill MB, Manuel K, Hassan SS, et al. The incidence and risk factors for developing dry eye after myopic LASIK. Am J Ophthalmol. 2006;141:438-45.
7)Korb DR, Herman JP, Blackie CA, Scaffidi RC, Greiner JV, Exford JM, et al. Prevalence of lid wiper epitheliopathy in subjects with dry eye signs and symptoms. Cornea. 2010;29:377-83.
8)Sambursky R, Davitt 3rd WF, Latkany R, Tauber S, Starr C, Friedberg M, et al. Sensitivity and specificity of a point-of-care matrix metalloproteinase 9 immunoassay for diagnosing inflammation related to dry eye. JAMA Ophthalmol. 2013;131:24-8.
9)Uchino M, Schaumberg DA, Dogru M, Uchino Y, Fukagawa K, Shimmura S, et al. Prevalence of dry eye disease among Japanese visual display terminal users. Ophthalmology. 2008;115:1982-8.
10)Uchino M, Yokoi N, Uchino Y, Dogru M, Kawashima M, Komuro A, et al. Prevalence of dry eye disease and its risk factors in visual display terminal users: the Osaka study. Am J Ophthalmol. 2013;156:759-66.